KLRC1 and chronic myelogenous leukemia, BCR-ABL1 positive: Our results highlight the dual effects of dasatinib in direct inhibition of ABL kinase and in immunomodulation through NKG2A down-regulation, contributing to accelerated molecular responses (MR) in CML.